We are in the 4th year of AMNOG. After 38 months, 68 benefit assessments were available. Their results have been and continue to be widely discussed. The topic of price negotiations and the resulting savings potential are also regularly the focus of interest. But what about the effects of the AMNOG processes on everyday care? How have new active ingredients become established on the market depending on their benefit assessment? This article aims to provide the first (cautious) highlights of this – from the perspective of a data service provider.

Read more